COMMUNIQUÉS West-GlobeNewswire

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
02/07/2026
REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
LIXTE COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS
02/07/2026
-Transaction Transforms LIXTE to New Growth Sector Addressing Multi-Billion-Dollar Market of Mobile, Utility-Grade Battery Energy Storage Systems- -Company Plans Corporate Name Change to NOMAD Power Solutions BOCA RATON [...]
SRX Global Makes Strategic Investment in Critical and Precious Minerals Development Company, Greenland Mines
02/07/2026
NORTH PALM BEACH, Fla., July 02, 2026 (GLOBE NEWSWIRE) -- SRX Global, Inc. (NYSE American: SRXH) (the "Company", or “SRX”), an AI-enabled platform dedicated to generating returns across high-conviction operating [...]
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
02/07/2026
Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (Nasdaq: CLRO), and change the listed company’s name and ticker to Cortigent Holdings, Inc. (d/b/a Cortigent) and “CRGT” [...]
New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
02/07/2026
- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech’s CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows - Demonstrates [...]
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
02/07/2026
BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a [...]
Qolab Announces $54.2 Million Series B Financing and Commitments Led by UC Investments to Accelerate the Future of Quantum Computing
02/07/2026
Announcement made during the 75th Lindau Nobel Laureate Meeting highlights growing collaboration among Qolab, Nobel Laureate Dr. John Martinis and the University of California innovation ecosystem SANTA BARBARA, Calif [...]
Zelluna ASA - Grant of Share Options
02/07/2026
Oslo, 2 July 2026: On the basis of the authorization granted by the General Meeting on 23 April 2026 for the Board of Directors of Zelluna ASA (the “Company”, OSE ticker “ZLNA”) to issue shares to employees and board [...]
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
02/07/2026
Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic [...]
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02/07/2026
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Flyte Announces Successful Launch of New Direct-to-Consumer Booking Platform
02/07/2026
Revenue Increased Sequentially Approximately 170% from Q1 to Q2 (QoQ) as Customer Adoption Accelerates Across Key Travel Markets FORT MILL, S.C., July 02, 2026 (GLOBE NEWSWIRE) -- Flyte, a subsidiary of Catheter [...]
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions
02/07/2026
SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
02/07/2026
Kirlew will lead Integra’s global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution. PRINCETON, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences [...]
Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting
02/07/2026
- Presentation Highlights Business Progress, Product Development Milestones, and Matters for Stockholder Consideration- TUCSON, Ariz., July 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard [...]
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
02/07/2026
CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors KANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical [...]
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
02/07/2026
New Taipei City, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization [...]
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
02/07/2026
Findings from 14 studies involving more than 8,000 patients show Prolaris adds insight beyond conventional clinical risk categories SALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN [...]
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
02/07/2026
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and [...]
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
02/07/2026
The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period MELBOURNE, Australia, July 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a [...]

Pages